PLD2 targeted by miR‐5132‐5p can attenuate cerulein‐induced AP in AR42J cells via the Nrf2/NFκB pathway, providing therapeutic targets for patients with AP. This evidence concerns the gene NFKB1 and alkaline phosphatase measurement.